Skip to content
Triangle logo TriangleGet started
← Ovarian Neoplasm

NCT00381888 · STUDY IN CONTEXT

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Venous thromboembolism is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system.

The number includes those patients who completed the study and are evaluable for this outcome measure.

→

secondary · POSTED

This is a count of patients who did not have a clot (thromboembolism) occur during the 4 weeks of study - attributed to the use of Fondaparinux (study dry). Prophylaxis is a measure taken for the prevention of a disease or condition.

These patients completed the study and are considered evaluable for this outcome measure.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-ovarian-neoplasm
nct id
NCT00381888
trial label
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
2
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00381888
    outcome key
    om-0000
    source section id
    NCT00381888-om-0000
    source outcome index
    0
    endpoint
    Number of Patients With Venous Thromboembolism at Week 4
    endpoint definition
    Venous thromboembolism is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system.
    time origin
    Week 4 (Days 28-35)
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    The number includes those patients who completed the study and are evaluable for this outcome measure.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00381888
    outcome key
    om-0001
    source section id
    NCT00381888-om-0001
    source outcome index
    1
    endpoint
    Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.
    endpoint definition
    This is a count of patients who did not have a clot (thromboembolism) occur during the 4 weeks of study - attributed to the use of Fondaparinux (study dry). Prophylaxis is a measure taken for the prevention of a disease or condition.
    time origin
    Week 4
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    These patients completed the study and are considered evaluable for this outcome measure.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00381888
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Fondaparinux Patients Who Completed Study
    regimen
    This number includes all patients that completed 4 weeks of the study and were treated with 2.5 mg of Fondaparinux on days 1-28.
    analyzed count
    27
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00381888-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00381888
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Fondaparinux Patients Who Completed Study
    regimen
    This number includes all patients that completed 4 weeks of the study and were treated with 2.5 mg of Fondaparinux on days 1-28.
    analyzed count
    27
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00381888-om-0001#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00381888
    harm key
    EG000
    source section id
    NCT00381888-ae
    event group key
    EG000
    event group label
    All Patients Who Received at Least One Dose of Fondaparinux
    serious affected
    7
    serious at risk
    33
    other affected
    23
    other at risk
    33
    frequency threshold
    0
    collection period
    4 Weeks
    event definition
    33 of 44 patients received at least one dose of Fondaparinux and therefore have been assessed for toxicity.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice